Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985955 | 0.91 | F2RL3 (0.43) | ATMEPHX2KDM1AF2RL3ALOX5AP | |
| SCHEMBL24763109 | 0.80 | IL1B (0.38) | ATMEPHX2F2RL3ALOX5APFEN1 | |
| SCHEMBL22985956 | 0.79 | TP53 (0.43) | TP53HCRTR1HCRTR2 | |
| SCHEMBL21958025 | 0.79 | ABHD6 (0.37) | TP53 | |
| SCHEMBL6609250 | 0.75 | CHEK2 (0.56) | CHEK2ATMKDM1AHCRTR1HCRTR2 | |
| SCHEMBL8706834 | 0.73 | CHEK2 (0.44) | CHEK2KDM1ATP53HCRTR1HCRTR2 | |
| SCHEMBL6615093 | 0.73 | HCRTR1 (0.58) | CHEK2HCRTR1HCRTR2ALOX5APFEN1 | |
| SCHEMBL8703344 | 0.72 | MEN1 (0.45) | CHEK2KDM1ATP53HCRTR1HCRTR2 | |
| SCHEMBL4317069 | 0.72 | CHEK2 (0.52) | CHEK2KDM1AHCRTR1HCRTR2 | |
| SCHEMBL8706733 | 0.71 | TP53 (0.43) | CHEK2ATMKDM1ATP53HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683285-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | CHEK2 3366/4885ATM 3103/4885EPHX2 3054/4885 |
| US-10683285-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | CHEK2 3366/4885ATM 3103/4885EPHX2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.